RNA-based therapy brings new hope for an incurable blood cancer
Three thousand new cases of Mantle Cell Lymphoma (MCL), a form of blood cancer, appear in the United States each year. With a median survival span of only five to seven years, according to the Leukemia and Lymphoma Society, this disease is devastating, and new therapies are sorely needed.
One of the characteristics that defines MCL is heightened activity in the gene CCND1, which leads to the aggressive over-production of Cyclin D1, a protein that controls the proliferation of cells, explains Prof. Dan Peer of Tel Aviv University's Department of Cell Research and Immunology. In this disease, Cyclin D1 production spins out of control, producing a 3,000 to 5,000 fold increase.
Now, in an international collaboration between academia and industry, Prof. Peer has developed a new class of drugs based on RNA interference, which can repair or destroy faulty proteins and reprogram cells to act in normal ways. The drugs have the ability to kill off the mutated protein and stop the over-proliferation of cells. Their method, proven in experiments with human cells and published in the journal PLoS One, was generously supported by the Lewis Trust and the Israeli Science Foundation.
Academia and industry work for a cure
In the past, scientists have attempted and failed to knock out this protein in the quest to develop a cure for MCL. But despite the prevalent belief that Cyclin D1 is not an effective target for therapies, Prof. Peer and his fellow researchers, including his PhD student Shiri Weinstein and Dr. Rafi Emmanuel and the Sheba Medical Center's Prof. Arnon Nagler and Dr. Avigdor Abraham, knew there was cause for hope.
To prove their theory that Cyclin D1 was indeed an appropriate target for the treatment of MCL, the researchers turned to two companies considered world-experts in RNA, Alnylam Pharmaceuticals in Cambridge, Massachusetts and Integrated DNA Technologies in Iowa, both of which donated their time and resources to the project. Working in parallel, they were able to design potent RNA interference sequences to stop the production of Cyclin D1.
In MCL, Cyclin D1 is the exclusive cause of the over-production of B Lymphocytes, cells responsible for generating antibodies, explains Prof. Peer. This makes the protein a perfect target for RNA interference – because normal, healthy cells don't express the gene, therapies that destroy the gene will only attack cancer cells. The RNA interference that the researchers have developed targets the faulty Cyclin D1 within the cancerous cells. And when the cells are inhibited from proliferating, they sense they are being targeted and begin to "commit suicide," he says.
In the lab, the researchers have successfully used their RNA interference in human cells, a crucial step towards proving that Cyclin D1 can be targeted through the right interventions. "Ultimately, we want to be able to cure this disease, and I think we are on the way," says Prof. Peer. He hopes that their results might cause scientists to reconsider previous and unproductive results on the effectiveness of treating MCL by addressing aberrations of this protein.
Pairing with nano-delivery methods
The researchers are working to develop a mouse population with MCL to test their newly-developed therapies in vivo. Typically, new therapies for any disease are tested on human cells as well as mouse models in the lab before being taken to clinical trials in humans. But there has never before been a test using mice with this disease, says Prof. Peer, a deficiency that has limited the quality of research. The animal test will allow researchers to conduct a more cautious and in-depth investigation of this new class of drugs before moving to the clinical stage.
As for strategies for delivering the new therapy into the body, the researchers will make use of Prof. Peer's extensive work with nano-sized medical "submarines" which are designed to travel to the source of disease or disorder in the human body, and offload drugs inside specific cells or proteins as needed.
Journal reference: PLoS ONE
Provided by Tel Aviv University
- Cancer protein discovery may aid radiation therapy Jun 09, 2011 | not rated yet | 0
- Therapy may block expansion of breast cancer cells Nov 05, 2008 | not rated yet | 0
- Findings point to molecular 'Achilles heel' for half of breast cancer tumors Jan 15, 2008 | not rated yet | 0
- Researchers identify natural tumor suppressor Sep 09, 2008 | not rated yet | 0
- Drugs targeting chromosomal instability may fight a particular breast cancer subtype Feb 06, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
- More from Physics Forums - Medical Sciences
More news stories
A new study conducted using extensive medical records of over one million Israeli adolescents before military service shows clearly how exposure to the Israeli sun of young, light-skinned children increases substantially ...
Cancer 22 minutes ago | not rated yet | 0
A new measure of the heterogeneity – the variety of genetic mutations – of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer. In the May 20 issue ...
Cancer 4 hours ago | not rated yet | 0
Researchers at Mayo Clinic have developed a promising method to distinguish between pancreatic cancer and chronic pancreatitis—two disorders that are difficult to tell apart. A molecular marker obtained from pancreatic ...
Cancer 4 hours ago | not rated yet | 0
The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...
Cancer May 19, 2013 | not rated yet | 0
Research presented at Digestive Disease Week (DDW) explores new methods for managing digestive health through diet and lifestyle.
Cancer May 19, 2013 | not rated yet | 1
When tumours metastasise, they can block lymphatic vessels, as researchers from ETH Zurich have discovered using a new method. The lymphatic fluid subsequently has to find a new path through the tissue. Such ...
14 minutes ago | not rated yet | 0 |
(Medical Xpress)—Flinders University researchers are breaking new ground in a decade-long journey to pinpoint the function of two closely related proteins.
3 minutes ago | not rated yet | 0 |
Every 20 seconds, a limb is lost as a consequence of diabetic foot ulcer that does not heal. To date, medical solutions that can change this situation are very limited. In his doctoral thesis Yue Shen from the Industrial ...
13 minutes ago | not rated yet | 0
(Medical Xpress)—The feared Legionella pneumophila is responsible for legionellosis, an infectious disease that can lead to pneumonia. To infect humans, this pathogen has developed a complex method that allows it to camouflage ...
23 minutes ago | not rated yet | 0
Finnish researchers have shown that genetic marker information can improve risk evaluation of coronary heart disease. The study comprised over 24,000 Finnish subjects and was led by Professor Samuli Ripatti. The results revealed ...
20 minutes ago | not rated yet | 0
(Medical Xpress)—A powerful new way of imaging kidneys is providing scientists with insights into the importance of the body's filtering system and how it is affected by cardiovascular disease, stroke and ...
23 minutes ago | not rated yet | 0